Sacha Mann is currently building early stage life science and digital health companies. She was most recently the CEO of Biosys UK Limited, a clinical-stage microbiome company developing oral polyclonal antibodies as targeted gut modulators for various indications. Previously Sacha spent a decade in life science and healthcare venture capital with Inventages, Archangels (UK) and BDC Capital focused on biotech, medtech and diagnostics. She also worked in operational roles in business development, corporate finance, management consulting and R&D. Sacha has a MBA (Simon Fraser University), a MSc in Biotechnology (Johns Hopkins University), a BSc in Chemistry (University of British Columbia), and is a Kauffman Fellow. She founded the C100 in the UK to support the growth of Canadian entrepreneurs as they scale their businesses into Europe.